209
Last Update Posted: 2005-08-17
Recruiting has ended
All Genders accepted | 21 Years-50 Years |
0 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Buprenorphine Dosing Interval - 5
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
Eligibility
Relevant conditions:
Opioid-Related Disorders
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov